Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission

Neuropsychopharmacology

Volumn 37, Issue 7, 2012, Pages 1717-1728

  Chernoloz, Olga ^a   El Mansari, Mostafa ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

depression; norepinephrine; norquetiapine; quetiapine; serotonin; SSRI

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; DRUG METABOLITE; ESCITALOPRAM; N DESALKYL QUETIAPINE; NORADRENALIN; QUETIAPINE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; ELECTROPHYSIOLOGY; HIPPOCAMPAL CA3 REGION; LOCUS CERULEUS; LOW DRUG DOSE; MALE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PERIKARYON; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT;

ADRENERGIC NEURONS; ANIMALS; ANTIPSYCHOTIC AGENTS; CA3 REGION, HIPPOCAMPAL; CITALOPRAM; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NOREPINEPHRINE; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 84861182426     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.18     Document Type: Article

References (60)

1. Aghajanian GK, Vandermaelen CP (1982a). Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure. J Neurosci 2: 1786-1792. (Pubitemid 13142753)
2. Aghajanian GK, Vandermaelen CP (1982b). Intracellular recording in vivo from serotonergic neurons in the rat dorsal raphe nucleus: Methodological considerations. J Histochem Cytochem 30: 813-814. (Pubitemid 13223738)
3. Aston-Jones G, Akaoka H, Charlety P, Chouvet G (1991). Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 11: 760-769.
4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70: 540-549.
5. Blier P, Szabo ST (2005). Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 66 (Suppl 8): 30-40. (Pubitemid 43004173)
6. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S et al (2011). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. J Affect Disord 128: 83-94.
7. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29: 252-265. (Pubitemid 39185866)
8. Chaput Y, Magnan A, Gendron A (2008). The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial. BMC Psychiatry 8: 73.
9. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS (2011). Grand challenges in global mental health. Nature 475: 27-30.
10. Curet O, De Montigny C, Blier P (1992). Effect of desipramine and amphetamine on noradrenergic neurotransmission: Electrophysiological studies in the rat brain. Eur J Pharmacol 221: 59-70.
11. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J Clin Psychiatry 70: 526-539.
12. De Montigny C, Wang RY, Reader TA, Aghajanian GK (1980). Monoaminergic denervation of the rat hippocampus: Microiontophoretic studies on pre- and postsynaptic supersensitivity to norepinephrine and serotonin. Brain Res 200: 363-376. (Pubitemid 10006959)
13. DeBattista C, Hawkins J (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23: 369-377.
14. Dremencov E, El Mansari M, Blier P (2007a). Noradrenergic augmentation of escitalopram response by risperidone: Electrophysiologic studies in the rat brain. Biol Psychiatry 61: 671-678. (Pubitemid 46328857)
15. Dremencov E, El Mansari M, Blier P (2007b). Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology 194: 63-72. (Pubitemid 47282734)
16. El Mansari M, Sánchez C, Chouvet G, Renaud B, Haddjeri N (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30: 1269-1277. (Pubitemid 40848081)
17. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P et al (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebocontrolled study. Int J Neuropsychopharmacol 13: 917-932.
18. Frankhuyzen AL, Mulder AH (1982). Pharmacological characterization of presynaptic a-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat. Eur J Pharmacol 81: 97-106. (Pubitemid 12087615)
19. Freedman JE, Aghajanian GK (1984). Idazoxan (RX 781094) selectively antagonizes a2-adrenoceptors on rat central neurons. Eur J Pharmacol 105: 265-272. (Pubitemid 14024440)
20. Gartside SE, Umbers V, Sharp T (1997). Inhibition of 5-HT cell firing in the DRN by non-selective 5-HT reuptake inhibitos:R studies on the role of 5-HT(1A) autoreceptors and noradrenergic mechanisms. Psychopharmacology 130: 261-268. (Pubitemid 27170359)
21. Ghanbari R, El Mansari M, Blier P (2011). Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology (Berl) 217: 61-73.
22. Gilmor ML, Owens MJ, Nemeroff CB (2002). Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 159: 1702-1710.
23. Goldstein JM, Arvanitis LA (1995). ICI 204,636 (seroquel): A dibenzothiazepine atypical antipsychotic. review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1: 50-73.
24. Haddjeri N, Blier P, De Montigny C (1998a). Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 51: 255-266. (Pubitemid 29202174)
25. Haddjeri N, Blier P, De Montigny C (1998b). Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT(1A) receptors. J Neurosci 18: 10150-10156. (Pubitemid 28543788)
26. Hatanaka K-I, Yatsugi S-I, Yamaguchi T (2000). Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol 395: 31-36. (Pubitemid 30227338)
27. Hertel P, Nomikos GG, Svensson TH (1997). Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br J Pharmacol 122: 1639-1646. (Pubitemid 28000191)
28. Hertel P, Nomikos GG, Svensson TH (1999). The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology 38: 1175-1184. (Pubitemid 29292406)
29. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33: 2303-2312.
30. Kandel ER, Spencer WA (1961). Electrophysiology of hippocampal neurons. II. After-potentials and repetitive firing. J Neurophysiol 24: 243-259.
31. Kasper S, Pail G (2010). Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 6: 23-31.
32. Katila H, Mezhebovsky I, Mulroy A (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. .
33. Lacroix D, Blier P, Curet O, De Montigny C (1991). Effects of longterm desipramine administration on noradrenergic neurotransmission: Electrophysiological studies in the rat brain. J Pharmacol Exp Ther 257: 1081-1090.
34. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H (2010). Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial. Depress Anxiety 27: 964-976.
35. Lindsay DeVane C (2001). Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 40: 509-522.
36. Mallard NJ, Hudson AL, Nutt DJ (1992). Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br J Pharmacol 106: 1019-1027.
37. Manta S, Dong J, Debonnel G, Blier P (2009). Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J Psychiatry Neurosci 34: 272-280.
38. Maura G, Gemignani A, Raiteri M (1985). a2-adrenoceptors in rat hypothalamus and cerebral cortex: Functional evidence for pharmacologically distinct subpopulations. Eur J Pharmacol 116: 335-339. (Pubitemid 16191828)
39. McElroy SL, Guerdjikova A, Mori N, Keck Jr PE (2010). Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 19: 1527-1544.
40. McIntyre A, Gendron A, McIntyre A (2007). Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. Depress Anxiety 24: 487-494. (Pubitemid 350086262)
41. Mongeau R, Blier P, De Montigny C (1993). In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of a2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 347: 266-272. (Pubitemid 23093650)
42. Mongeau R, De Montigny C, Blier P (1994). Electrophysiologic evidence for desensitization of a2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10: 41-51. (Pubitemid 24074297)
43. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebocontrolled randomized trials. Am J Psychiatry 166: 980-991.
44. Nemeroff CB (2005). Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66 (SUPPL 8): 13-21. (Pubitemid 43004171)
45. Nutt DJ (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69(Suppl E1): 4-7.
46. Papakostas GI (2005). Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol 6: 209-220.
47. Papakostas GI (2009). Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 70 (Suppl 6): 16-25.
48. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic press, 4th edition. .
49. Ranck JB (1975). Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson LR, editor. The hippocampus. New York: Plenum Press, 207-244.
50. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124: 57-73. (Pubitemid 26112775)
51. Seager MA, Barth VN, Phebus LA, Rasmussen K (2005). Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: Implications for bipolar disorder. Psychopharmacology 181: 126-133. (Pubitemid 41440923)
52. Shelton RC, Osuntokun O, Heinloth AN, Corya SA (2010). Therapeutic options for treatment-resistant depression. CNS Drugs 24: 131-161.
53. Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH (1999). Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: Inhibition of dorsal raphe cell firing and the role of 5-HT(1A) receptor activation. Neuropsychopharmacology 21: 622-631. (Pubitemid 29486630)
54. Stahl SM (2010). Enhancing outcomes from major depression: Using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectrums 15: 79-94.
55. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T et al (2007). Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology 190: 373-382. (Pubitemid 46155646)
56. Szabo ST, de Montigny C, Blier P (2000). Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 3: 1-11. (Pubitemid 30354447)
57. Szabo ST, Blier P (2001). Serotonin 1A receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABAA receptors: A microiontophoretic study in the rat locus coeruleus. Synapse 42: 203-212. (Pubitemid 33027294)
58. Szabo ST, Blier P (2002). Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT2a receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 302: 983-991. (Pubitemid 34920218)
59. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60: 1079-1088. (Pubitemid 37429647)
60. Weisler R, Joyce JM, McGill L, Lazarus A, Szamosi J, Eriksson H (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectrums 14: 299-313.